Fundraising FoxIstari Oncology
Morrisville, US · Delaware corporation · 1 known investors
Find your way into Istari Oncology
Sign up to see every warm intro you have to Istari Oncology
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Istari Oncology team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Clinical-stage biotech developing immuno-oncology platforms for solid tumors including glioblastoma and melanoma.
Founders & leadership
MB
Marc BanjakGeneral Counsel and Corporate Secretary2021–2021Marc Banjak is an executive officer at Istari Oncology with extensive experience in legal operations for medical device and pharmaceutical companies, including contract negotiation and regulatory compliance.
WG
William G. NicholsExecutive
MR
Matthew R. StoberExecutive
Board
RB
Robert BonczekBoard director
RC
Raymond CheongBoard director
VS
Victor SandorBoard director
SN
Sean NolanBoard director
DP
Dani P. BolognesiBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$48.6M disclosed across 3 rounds · 2017–2021
▶$43.5MraisedApr 2021 · 17 investors · BiotechnologyRule 506(b)
▶$43.5MraisedApr 2021 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert BonczekDirector
- Raymond CheongDirector
- Marc BanjakExecutive Officer
- Matthew W. FarberExecutive Officer
- William G. NicholsExecutive Officer
- Victor SandorDirector
- Sean NolanDirector
- Matthew R. StoberExecutive Officer, Director
- Dani P. BolognesiDirector
- Offering amount
- $70M
- Amount sold
- $43.5M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedMay 2017 · 10 investors · BiotechnologyRule 506(b)
▶$1.1MraisedMay 2017 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert BonczekExecutive Officer, Director
- Dani P. BolognesiExecutive Officer, Director
- Henry FriedmanExecutive Officer
- Timothy J. CreechExecutive Officer
- Darell D. BignerDirector, Promoter
- Offering amount
- $4M
- Amount sold
- $1.1M
- First sale
- May 2017
- Incorporated
- Corporation, North Carolina, 2014
- Federal exemptions
- 06b
▶$4MraisedFeb 2017 · 1 investors · Other Health CareRule 506(b)
▶$4MraisedFeb 2017 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Darell D. BignerExecutive Officer, Director, Promoter
- Timothy J. CreechExecutive Officer
- Dani P. BolognesiExecutive Officer, Director
- Henry FriedmanExecutive Officer
- Robert BonczekExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Jan 2017
- Incorporated
- Corporation, North Carolina, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Istari Oncology do?
- Clinical-stage biotech developing immuno-oncology platforms for solid tumors including glioblastoma and melanoma.
- Who are Istari Oncology's investors?
- Istari Oncology's investors include Pappas Capital.
- How much funding has Istari Oncology raised?
- Istari Oncology has disclosed $48.6M raised across 3 rounds.
- Where is Istari Oncology headquartered?
- Istari Oncology is headquartered in Morrisville, US.